首页|舒利迭联合顺尔宁对中重度AECOPD患者的肺功能改善效果及预后研究

舒利迭联合顺尔宁对中重度AECOPD患者的肺功能改善效果及预后研究

扫码查看
目的 研究舒利迭联合顺尔宁对中重度AECOPD患者的肺功能改善效果及预后.方法 选择2014年1月~2016年6月温州市瑞安市塘下人民医院接诊的78例中重度AECOPD患者进行研究.按照入院顺序随机分为观察组和对照组,每组各39例.对照组给予常规抗感染、化痰、氧疗、吸入舒利迭.观察组在对照组基础上加用顺尔宁治疗.比较2组患者一般临床资料、临床疗效、临床症状开始改善时间、住院时间、治疗后5d的血气分析动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)以及肺功能第一秒用力呼气容积(FEV1)、呼气峰值流速(PEF)、第一秒用力呼气容积比上用力肺活量(FEV1/FVC)、最大呼气中期流速(MMEF).结果观察组和对照组患者的一般临床资料相比较无统计学意义.观察组与对照组的治疗有效率分别为97.44%与87.18%,观察组的临床疗效明显优于对照组,差异有统计学意义(u=2.2805,P<0.05).观察组的术后住院时间、临床症状开始改善时间均短于对照组,差异有统计学意义(P<0.05);观察组治疗后5d的PaO2高于对照组,而治疗后5d的PaCO2低于对照组,差异有统计学意义(P<0.05).治疗前2组患者的肺功能无统计学差异,治疗后,观察组的肺功能(包括FEV1、PEF、FEV1/FVC、MMEF)均优于对照组,差异有统计学意义(P<0.05).结论 舒利迭联合顺尔宁治疗中重度AECOPD能够明显提高治疗效果,明显改善患者的肺功能.
Effect of seretide combined with singulair on lung function improvement and prognosis of moderate to severe AECOPD
Objective To study the effect improvation of lung function and prognosis of singulair and seretide for moderate to severe AECOPD . Methods 78 patients associated with moderate to severe AECOPD from January 2014 to June 2016 in our hospital were researched.They were divided randomly into observation and control groups according to the order of admission, 39 cases in each group.In the control group, they were treated by conventional anti-infective, expectorant, oxygen, suction seretide.In the observation group, using singulair on the basis of the control group.Clinical data, clinical efficacy, clinical symptoms begin to improve time, hospitalization time, blood gas analysis (PaO2, PaCO2) after five days and pulmonary function after treatment forced expiratory volume in one second ( FEV1 ) , call gas peak velocity ( PEF) , forced expiratory volume in one second than the forced vital capacity (FEV1/FVC), maximum mid-expiratory flow rate (MMEF) were compared with each other.Results Their clinical data of patients and other general information and basic condition had no significant difference between each other.The effective rate of observation group and control group were 97.44%and 87.18%, clinical effecicy of observation group was better than the control group, the difference was statistically significant (u=2.2805, P<0.05).Postoperative hospital stay, time of symptoms began to improve of the observation group were shorter than the control group, the difference was statistically significant (P<0.05), PaO2 of 5-day post-treatment of observation group was higher, and PaCO2 was lower, the difference was statistically significant (P<0.05).Lung function of two groups of patients had no significant difference before treatment, after treatment, pulmonary function in the observation group (including FEV1, PEF, FEV1/FVC, MMEF) was better than the control group, the difference was statistically significant (P<0.05).Conclusion Seretide combined with singulair to treat severe AECOPD has a good effect, it can significantly improve the therapeutic effect and improve the patient's lung function.

seretidesingulaircombineAECOPD

黄小春、戴其二、戴凌峰

展开 >

温州市瑞安市塘下人民医院 药房,浙江 瑞安 325204

温州市瑞安市塘下人民医院 耳鼻咽喉科,浙江 瑞安 325204

温州市瑞安市塘下人民医院 内科,浙江 瑞安 325204

舒利迭 顺尔宁 联合 AECOPD

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(2)
  • 4
  • 12